Literature DB >> 11497545

Availability of HIV care in Central America.

D A Wheeler1, E G Arathoon, M Pitts, R A Cedillos, T E Bu, G D Porras, G Herrera, N R Sosa.   

Abstract

Central America is an area with a growing human immunodeficiency virus (HIV) epidemic, but with marked limitations in its health care infrastructure. Estimated adult HIV infection rates range from 0.20% in Nicaragua to 2.01% in Belize. Hospitals and clinicians with experience in HIV care exist mainly, if not only, in capital cities and principal economic centers. Nationally sponsored social security systems in each country consistently offer a wider range of services than do ministry of health systems. Estimated access to the social security system ranges from 0% in Belize and 10% of the population in Honduras to 95% in Costa Rica. Combination antiretroviral therapy is not available through the ministries of health and zidovudine is only sporadically available for prevention of perinatal transmission. Combination therapy is available through the social security system in the countries of Guatemala, Panama, and Costa Rica only. A wide variety of antiretroviral agents are available through private pharmacies in all countries except Belize. With the exception of Costa Ricans, most people with HIV infection in Central America have limited access to HIV-specific health services and limited or no access to antiretroviral agents.

Entities:  

Mesh:

Year:  2001        PMID: 11497545     DOI: 10.1001/jama.286.7.853

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

1.  Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country.

Authors:  Karidia Diallo; Wendy E Murillo; Ivette Lorenzana de Rivera; Jan Albert; Zhiyong Zhou; John Nkengasong; Guoqing Zhang; Jennifer F Sabatier; Chunfu Yang
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-28

2.  The epidemiology of clinically apparent HIV infection in Nicaragua.

Authors:  A J Matute; E Delgado; J J Amador; A I M Hoepelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-27       Impact factor: 3.267

3.  HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

Authors:  Yaxelis Mendoza; Juan Castillo Mewa; Alexander A Martínez; Yamitzel Zaldívar; Néstor Sosa; Griselda Arteaga; Blas Armién; Christian T Bautista; Claudia García-Morales; Daniela Tapia-Trejo; Santiago Ávila-Ríos; Gustavo Reyes-Terán; Gonzalo Bello; Juan M Pascale
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.